(RFL) Rafael Holdings - Ratings and Ratios

Rafael Holdings, Inc. is a multifaceted company with a diverse portfolio of interests in clinical-stage pharmaceuticals, early-stage pharmaceutical companies, and commercial real estate assets across the United States and Israel. The companys operations are segmented into three primary areas: Healthcare, Infusion Technology, and Real Estate. Through its Healthcare segment, Rafael Holdings focuses on developing therapies that target the metabolic disparities between normal cells and cancer cells, capitalizing on the unique characteristics of cancer cell metabolism to create innovative treatments.

The companys lead drug candidate, CPI-613 (devimistat), is a stable analog of lipoates acylated catalytic intermediates. It is currently under investigation in multiple clinical trials, including a Phase 2 open-label multi-cohort study assessing CPI-613 in combination with hydroxychloroquine and 5-fluorouracil or gemcitabine for patients with advanced, chemorefractory colorectal, pancreatic, or other solid cancers. Additionally, a Phase 1 dose-escalation study is evaluating CPI-613 in combination with chemoradiation for patients with pancreatic adenocarcinoma. These trials indicate a robust pipeline focused on addressing significant unmet medical needs in oncology.

Beyond CPI-613, Rafael Holdings is developing other promising pharmaceutical candidates, including Promitil, a prodrug designed for targeted delivery of mitomycin-C, which has completed Phase 1A and 1B clinical studies for patients with advanced cancers. The company is also advancing Folate-targeted Promitil (Promi-Fol) for the local treatment of superficial bladder cancer and Promi-Dox, a potent dual-drug liposome targeting various tumors. These developments underscore the companys commitment to innovative cancer treatments and its potential to address a range of oncological conditions.

Rafael Holdings diverse interests also extend to the development of surgical and procedural devices, such as orthopedic arthroscopy instruments for Carpal Tunnel syndrome, further broadening its healthcare technology footprint. With its incorporation in 2017 and headquarters in Newark, New Jersey, the company has established a presence in the biopharmaceutical and real estate sectors.

Analyzing the provided and , we observe that RFLs stock has been trading near its 52-week low, with a last price of $1.37. The stock is below its SMA20, SMA50, and SMA200, indicating a bearish trend. The ATR of 0.11 represents an 8.04% volatility, suggesting significant price movements. With a Market Cap of $56.54M USD and a negative P/E ratio, the company is in a growth phase with substantial investment in R&D. Given the ongoing clinical trials and the potential breakthroughs in cancer treatment, a forecast based on the current data could indicate a potential rebound if the clinical trials yield positive results. A successful outcome could lead to a significant increase in stock price, potentially targeting the 52-week high of $2.34 or beyond, driven by improved investor sentiment and increased market capitalization. However, the negative RoE of -64.87% highlights the risks associated with investing in a company with significant losses. Investors should closely monitor the progress of Rafael Holdings clinical trials and adjust their strategies accordingly.